Skip to main content
SpringerLink
Log in

Evogliptin: First Global Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Evogliptin (Suganon™) is an orally bioavailable, selective dipeptidyl peptidase-4 (DPP-4; CD26 antigen) inhibitor being developed by Dong-A ST for the treatment of type 2 diabetes mellitus. DPP-4 inhibitors control glucose levels by preventing the breakdown of the incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), which stimulate insulin secretion in response to the increased levels of glucose in the period following meals. In October 2015, evogliptin received its first global approval in South Korea for blood glucose control in patients with type 2 diabetes mellitus. This article summarizes the milestones in the development of evogliptin leading to this first approval for type 2 diabetes mellitus.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. International Diabetes Federation. Global guideline for type 2 diabetes. 2012. http://www.idf.org/sites/default/files/IDF-Guideline-for-Type-2-Diabetes.pdf. Accessed 12 Oct 2015.

  2. Ministry of Food and Drug Safety. MFDS approval of a new, domestically-developed, oral antihyperglycaemic agent [in Korean] [media release]. 2 Oct 2015. http://www.mfds.go.kr/index.do?mid=675&pageNo=1&seq=28999&cmd=v.

  3. PipelineReview.com. Dong-A ST’s DPP4 inhibitor, SUGANON, got approved for type 2 diabetes in Korea. 2015. http://www.pipelinereview.com/index.php/2015100259148/Small-Molecules/Dong-A-STs-DPP4-inhibitor-SUGANON-got-approved-for-type-2-diabetes-in-Korea.html. Accessed 13 Oct 2015.

  4. Dong-A ST. 2Q 2015 Performance Results. 2015. http://en.donga-st.com/B05.da?method=IRResourceList. Accessed 13 Oct 2015.

  5. Dong-A ST. 2014 Annual report. 2015. http://en.donga-st.com/Pass.da?viewPath=/b05/IRReport. Accessed 13 Oct 2015.

  6. Dong-A ST. 1Q 2015 Performance results. 2015. http://en.donga-st.com/B05.da?method=IRResourceList. Accessed 13 Oct 2015.

  7. Luye Pharma Group, Dong A. Pharma Co Ltd. Luye Pharma obtains the exclusive license of new antidiabetic preparation in China from Dong-A Phama Co., Ltd.—DPP-IV inhibitor DA-1229 [media release]. 17 Feb 2012.

  8. Kim HJ, Kwak WY, Min JP, et al. Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem Lett. 2011;21(12):3809–12.

    Article  CAS  PubMed  Google Scholar 

  9. Chen XW, He ZX, Zhou ZW, et al. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clin Exp Pharmacol Physiol. 2015;42(10):999–1024.

    Article  CAS  PubMed  Google Scholar 

  10. Kim M-K, Chae YN, Kim HD, et al. DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes. Life Sci. 2012;90(1):21–9.

    Article  CAS  PubMed  Google Scholar 

  11. Gu N, Park MK, Kim TE, et al. Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. Drug Des Devel Ther. 2014;8:1709–21.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Cho JM, Jang HW, Cheon H, et al. A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing beta-cell replication and neogenesis. Diabetes Res Clin Pract. 2011;91(1):72–9.

    Article  CAS  PubMed  Google Scholar 

  13. Kim TE, Lim KS, Park MK, et al. Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study. Clin Ther. 2012;34(9):1986–98.

    Article  CAS  PubMed  Google Scholar 

  14. Park KJ, Shim HJ. Metabolism and excretion of [14C]evogliptin, a DPP-4 inhibitor, in rats [abstract no. P323]. Drug Metab Rev. 2014;45(Suppl 1):195.

    Google Scholar 

  15. Won JC. The new DPP-IV inhibitor: evogliptin. Results of clinical trials. In: 2015 International Congress on obesity and metabolic syndrome—satellite symposium 3. http://www.icomes.or.kr/program/sub02_11.html. Accessed 30 Oct 2015.

  16. Jung CH, Park CY, Ahn KJ, et al. A randomized, double-blind, placebo-controlled, phase II clinical trial to investigate the efficacy and safety of oral DA-1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exercise. Diabetes Metab Res Rev. 2015;31(3):295–306.

    Article  CAS  PubMed  Google Scholar 

  17. Dong-A ST. 4Q 2014 performance results. 2015. http://en.donga-st.com/B05.da?method=IRResourceList. Accessed 20 Oct 2015.

Download references

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand

    Paul L. McCormack

Authors
  1. Paul L. McCormack
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul L. McCormack.

Ethics declarations

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. P. L. McCormack is a salaried employee of Adis, Springer SBM.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McCormack, P.L. Evogliptin: First Global Approval. Drugs 75, 2045–2049 (2015). https://doi.org/10.1007/s40265-015-0496-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-015-0496-5

Keywords

Search

Navigation